PL413558A1 - Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this molecule - Google Patents
Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this moleculeInfo
- Publication number
- PL413558A1 PL413558A1 PL413558A PL41355815A PL413558A1 PL 413558 A1 PL413558 A1 PL 413558A1 PL 413558 A PL413558 A PL 413558A PL 41355815 A PL41355815 A PL 41355815A PL 413558 A1 PL413558 A1 PL 413558A1
- Authority
- PL
- Poland
- Prior art keywords
- molecule
- growth factor
- fibroblast
- modified
- modified molecule
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Cytokina czynnik wzrostu fibroblastów-1 (FGF-1), należy do dużej grupy białek liczącej 23 warianty o podobnej strukturze, pełniących pokrywające się, lecz nie identyczne funkcje. Pobudzają one podziały mitotyczne wielu typów komórek, spośród których najważniejsze to fibroblasty, komórki śródbłonka naczyń i keratynocyty. Przedmiotem zgłoszenia jest sztucznie skonstruowana cząsteczka FGF-1 trzeciej generacji o ulepszonych właściwościach biologicznych i strukturalnych oraz o dodatkowych właściwościach pozwalających na osiągnięcie przewagi technologicznej.The cytokine fibroblast growth factor-1 (FGF-1) belongs to a large group of proteins with 23 variants of a similar structure, which perform overlapping but not identical functions. They stimulate mitotic division of many types of cells, among which the most important are fibroblasts, vascular endothelial cells and keratinocytes. The subject of the application is an artificially constructed third generation FGF-1 molecule with improved biological and structural properties as well as additional properties enabling technological advantage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL413558A PL228868B1 (en) | 2015-08-13 | 2015-08-13 | Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this molecule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL413558A PL228868B1 (en) | 2015-08-13 | 2015-08-13 | Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL413558A1 true PL413558A1 (en) | 2017-02-27 |
| PL228868B1 PL228868B1 (en) | 2018-05-30 |
Family
ID=58091997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL413558A PL228868B1 (en) | 2015-08-13 | 2015-08-13 | Modified molecule of fibroblast 1 growth factor, molecule of nucleic acid coding the modified molecule of fibroblast 1 growth factor, application of the modified molecule of fibroblast 1 growth factor and pharmaceutical composition containing this molecule |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL228868B1 (en) |
-
2015
- 2015-08-13 PL PL413558A patent/PL228868B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL228868B1 (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2657060T3 (en) | Fusokines involving cytokines with strongly reduced receptor binding affinities | |
| PE20110358A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE DEFECTS WITH PLACENTARY CELL POPULATIONS | |
| PE20250757A1 (en) | INTERLEUKIN 21 MUTEINS AND TREATMENT METHODS | |
| BR112014018630A2 (en) | bleaching of chondroitin sulfate glycans | |
| BR112020026125A8 (en) | SUPERIOR OLIGONUCLEOTIDE OR 5'-CAP-TRINUCLEOTIDE COMPOUNDS AND THEIR USES IN RNA STABILIZATION, PROTEIN EXPRESSION AND IN THERAPY | |
| CO2017009954A2 (en) | Domains designed with ankyrine repeats with binding specificity for serum albumin | |
| CO2019004006A2 (en) | Method to increase the secretion levels of interleukin 2 and its derived proteins | |
| UY38701A (en) | MOLECULES OF BINDING TO CD19, CONJUGATES, COMPOSITIONS THAT INCLUDE THEM AND USES OF THE SAME | |
| CL2008001674A1 (en) | Simple variable domain (dab) of vascular endotlial growth anti-fator immunoglobulin (vegf); nucleoic acid that encodes it; vector and host cell; Method of production; antagonist of vegf comprising the dab; composition comprising the antagonist; and use of the antagonist to prepare a medication. | |
| BR112017027498A2 (en) | antibody, nucleic acid, compound, composition, and method for treating a patient with a disease. | |
| MX395421B (en) | ARTIFICIAL NUCLEIC ACID MOLECULES. | |
| PE20140867A1 (en) | AXMI-115, AXMI-113, AXMI-005, AXMI-163 AND AXMI-184: INSECTICIDE PROTEINS AND METHODS FOR THEIR USE | |
| BR112017007765A2 (en) | adenosine deaminase-2 (ada2) compositions, variants thereof and methods of using it | |
| BR112015031639A2 (en) | target integration | |
| BR112014004130A8 (en) | Isolated polynucleotides and polypeptides and methods of using them to increase plant production and/or agricultural characteristics | |
| BR112015017338A8 (en) | isolated antibody or protein, its pharmaceutical composition, its use, its production process, isolated nucleic acid molecule, cloning or expression vector, and host cell | |
| AR092076A1 (en) | HOMODIMERIC PROTEINS | |
| BR112015021993A2 (en) | Antioxidant cell culture compositions and methods for producing polypeptide | |
| BR112015022210A8 (en) | antibody formulations | |
| CL2022001655A1 (en) | Engineered variants of acid alpha-glucosidase. | |
| BRPI0821034A8 (en) | RECOMBINANT INFLUENZA B VIRUS, ITS USE, METHOD OF PREPARATION, COMPOSITION OF VACCINE CONTAINING O AND ITS M GENE, AS WELL AS ISOLATED NUCLEIC ACID, INFLUENZA M VIRUS MOLECULE AND ITS USE AND METHOD TO INCREASE THE GROWTH RATE OF REPLICATION DEFECTIVE INFLUENZA B VIRUSES | |
| BRPI0813913A8 (en) | NUCLEIC ACID MOLECULE, RECOMBINANT NUCLEIC ACID SEQUENCE, HOST CELL, METHODS FOR PRODUCING RECOMBINANT HUMAN FSH, AND FOR PRODUCING THE HOST CELL, AND, USE OF A NUCLEIC ACID SEQUENCE. | |
| JP2016027797A5 (en) | ||
| CO2021005083A2 (en) | Miniaturized dystrophins and their uses | |
| MX382488B (en) | STABLE NEURAL STEM CELLS COMPRISING AN EXOGENOUS POLYNUCLEOTIDE ENCODING A GROWTH FACTOR AND METHODS OF USING SAME. |